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Abstract
Objective: Fish or fish oil consumption may increase levels of total and high molecular weight (HMW)
adiponectin, a hormone associated with anti-inflammatory and insulin-sensitising effects, however it is not
known if the effects of the food and supplement are the same. The aim of this study was to compare the effect
of consuming fish and fish oil supplements on plasma total and HMW adiponectin concentrations in
overweight human participants.
Materials/Methods: 29 overweight and obese participants underwent a two week run-in period, followed by a
four week isocaloric dietary intervention which provided 1.8g of long chain omega-3 polyunsaturated fatty
acids (LC n-3 PUFA) in the form of either fish or fish oil supplements. Primary outcomes were changes in
plasma total and HMW adiponectin. Secondary outcomes were changes in anthropometric variables, plasma
insulin and glucose levels, and dietary intakes.
Results: Changes in plasma HMW adiponectin during the intervention period were significantly different
between groups (p=0.009). Mean HMW adiponectin increased by 0.29μg/mL in the ‘fish’ group and
decreased by 0.60μg/mL in the ‘supplement’ group. There were no significant changes in other
anthropometric and biochemical variables. Dietary data suggested the ‘fish’ group significantly increased their
fish (p=0.001) and dietary LC n-3 PUFA (p=0.001) consumption over the course of the study.
Conclusions: Short-term consumption of fish and fish oil supplements did not have the same effects on HMW
adiponectin levels. The impact of fish intake on HMW adiponectin levels may not be mediated by its LC n-3
PUFA content alone.
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Abstract 
 
Objective: Fish or fish oil consumption may increase levels of total and high molecular 
weight (HMW) adiponectin, a hormone associated with anti-inflammatory and insulin-
sensitising effects, however it is not known if the effects of the food and supplement are the 
same. The aim of this study was to compare the impact of fish and fish oil supplements on 
total and HMW adiponectin.  
Materials/Methods: 29 overweight participants underwent a two week run-in period, followed 
by a four week isocaloric dietary intervention which provided 1.8g of long chain omega-3 
polyunsaturated fatty acids (LC n-3 PUFA) in the form of either fish or fish oil supplements. 
Primary outcomes were changes in plasma total and HMW adiponectin. Secondary outcomes 
were changes in anthropometric variables, plasma insulin and glucose levels, and dietary 
intakes.  
Results: Changes in plasma HMW adiponectin during the intervention period were 
significantly different between groups (p=0.009). Mean HMW adiponectin increased by 
0.29ug/mL in the ‘fish’ group and decreased by 0.60ug/mL in the ‘supplement’ group. 
Similar trends were seen for total adiponectin however these did not reach statistical 
significance. There were no significant changes in other anthropometric and biochemical 
variables. Dietary data suggested the ‘fish’ group significantly increased their fish (p=0.001) 
and dietary LC n-3 PUFA (p=0.001) consumption over the course of the study. 
Conclusions: Short-term consumption of fish and fish oil supplements did not have the same 
effects on HMW adiponectin levels. The impact of fish intake on HMW adiponectin levels 
may not be mediated by its LC n-3 PUFA content alone.   
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Introduction 
 
Adiponectin, a hormone secreted by adipocytes, is known to play a role in mediating 
inflammation, as well as having anti-obesity and insulin sensitising effects [1, 2]. 
Adiponectin levels are lower in individuals suffering from obesity [3] or type II diabetes [4], 
and treatment with adiponectin in animal models improves insulin sensitivity and promotes 
weight loss [2, 5]. Adiponectin circulates in multimers of varying metabolic weights, 
including high molecular weight (HMW) adiponectin [6]. HMW is thought to be the more 
physiologically active form of adiponectin, with HMW adiponectin levels found to be a better 
predictor of insulin sensitivity and other components of the metabolic syndrome than total 
adiponectin concentrations [7].   
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There is evidence to suggest that consumption of either fish or fish oil supplements 
rich in long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) can increase 
adiponectin levels in both animal models [8-11] and humans [12-17]. This effect is thought to 
be mediated by the activation of Peroxisome Proliferator Activated Receptor γ (PPARγ) by 
LC n-3 PUFA, resulting in increased adiponectin synthesis in adipose tissue [18].  
It is currently unclear whether fish and fish oil supplements have the same effect on 
adiponectin synthesis and secretion. The concept of food synergy proposes that interaction 
between the bioactive compounds present in foods may be responsible for health benefits, 
rather than single nutrients alone [19, 20]. In accordance with this concept, research suggests 
that fish may have additional health benefits than those provided by fish oil alone [21, 22]. 
Historically, however, very few studies compare the effects of fish and fish oil on any health 
outcome, including circulating adiponectin concentrations. Futhermore, most studies 
investigating the effects of foods on adiponectin levels have failed to measure changes in 
HMW adiponectin, despite its known physiological importance.  
Furthermore, single nucleotide polymorphisms (SNPs) in the gene encoding for 
adiponectin, ADIPOQ, can influence circulating levels of adiponectin, with individuals  
carrying the C allele of the ADIPOQ SNP rs266729 have been found to have lower levels of 
circulating adiponectin than those homozygous for the G allele [23]. Similarly, SNPs in the fat mass 
and obesity-associated (FTO) gene may influence adiponectin levels as well as health 
outcomes [24, 25], and Caucasian women who were homozygous for the A allele of the FTO SNP 
rs9939609 have been found have lower circulating levels of adiponectin than those homozygous for 
the T allele [24]. Therefore, such variations have the potential to pre-dispose individuals to 
altered levels of adiponectin and could thus confound the results of dietary interventions. 
However, no known study assessing the effect of fish or LC n-3 PUFA on adiponectin levels 
has measured SNPs in ADIPOQ or FTO genes. 
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 The aim of this study was to compare the effects of consumption of fish and fish oil 
supplements, providing a similar amount of LC n-3 PUFA, on total and HMW adiponectin 
levels in overweight humans.   
 
Materials and Methods 
 
Study design: A six week pilot study was conducted with overweight adults randomised to 
one of two parallel arms: fish diet group (‘fish’) and fish oil group (‘supplement’). 
Participants were block randomised by gender and body mass index (BMI) category (25-
30kg/m2 and 30-35kg/m2). Both groups underwent a two week run-in period (t= -2-0 weeks), 
designed to orient them to the study protocol and to observe any reductions in weight 
following commencement of the study. Following this two week run-in period, both groups 
commenced the four week dietary intervention (t=0–4 weeks). Primary outcomes were 
change in total and high molecular weight (HMW) plasma adiponectin concentrations. 
Secondary outcomes included changes in anthropometric variables, insulin and glucose 
levels, and dietary intakes. 
 
Participants were recruited via advertisements sent to University of Wollongong 
general and academic staff and flyers distributed at University of Wollongong events.  
Inclusion criteria: aged 18–65 years, willing to consume fish, BMI >25 and <37kg/m2, waist 
circumference >94cm for men, >80cm for women, generally well. 
Exclusion criteria: Diabetes mellitus, impaired renal function, smoking, not weight stable for 
the past six months, food allergies or habits inhibiting compliance with the study design, 
illiteracy and inadequate conversational English, currently taking medications including 
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thiazolidinediones, valproic acid, ACE inhibitors, and glucocorticoids, pregnancy/lactation, 
high consumption of fish (three to four serves per week) 
 
Dietary intervention: For six weeks both groups were advised to consume an isocaloric diet 
for weight maintenance (meeting estimated energy requirements [26] with 1.25 physical  
activity factor), of 25% protein, 45% carbohydrate, and 30% fat. Diets referred to low fat 
staple foods (fruit, vegetables, cereals, lean meat, low fat milk and yoghurt) and small 
amounts of nuts, seeds, spreads and oils. Due to the effects of changes in alcohol 
consumption on adiponectin levels [27, 28], participants were advised to maintain their 
normal level of alcohol consumption over the course of the study. Following the two week 
run-in period, participants in the ‘fish’ group were provided with three serves of 135g salmon 
(Birds Eye Atlantic Salmon Fillets, Simplot Australia), two serves of 66g sardines (adjusted 
for percentage fish in total canned product; John West Sardines in Tomato Sauce, Simplot 
Australia) and one serve of 55.1g tuna (adjusted for percentage fish; John West Tuna 
Tempters Lemon and Cracked Pepper, Simplot Australia) per week for four weeks. Due to an 
inability to consume sardines, one participant was provided with four serves of 135g salmon 
and one serve of 55.1g tuna per week. The fish provided was designed to contribute 
approximately 1.86g of LC n-3 PUFA per day (approximately 812mg Eicosapentaenoic acid 
[EPA] + 1044mg Docosahexaenoic acid [DHA]). During the dietary intervention period, 
participants in the ‘supplement’ group were given three fish oil supplements per day, to 
provide 1.8g of total LC n-3 PUFA (1055.1mg EPA + 744.9mg DHA; Blackmores Omega 
Daily). Participants in the ‘supplement’ group were not given any specific advice regarding 
fish consumption. 
 Diet histories (DH) interviews [29] were collected at t= -2 weeks and t=4 weeks to 
identify changes from habitual diets. Dietary intake was calculated using the Foodworks 
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nutrient analysis software (Xyris Pty Ltd, Highgate Hill, QLD, Australia, Version 6, 2009), 
using the ‘AUSNUT2007 Brands’ and ‘AUSNUT2007 Foods’ nutrient databases [30]. Fish 
intake was calculated as grams of fish consumed per week. 
All remaining fish and supplements were collected at the end of the study to measure 
compliance. Returned supplements were used to calculate LC n-3 PUFA intake in the 
‘supplement’ group in addition to dietary LC n-3 PUFA measured by DH interview.  
 All participants were advised to maintain their normal level of physical activity over 
the duration of the study. Habitual physical activity was assessed prior to the run-in period 
(t= -2 weeks) and at the end of the study (t=4 weeks) via the Baecke questionnaire [31]. 
 
Anthropometry: Body weight and percentage body fat were measured in an upright position 
at t= -2, 0, 4 weeks, in minimal clothing and without shoes using scales with a bioelectrical 
impedance component (Tanita TBF-662). Waist circumference was measured at t= -2, 0, 4 
weeks with a flexible tape measure. 
 
Insulin, glucose, plasma fatty acids and adiponectin: were measured in the morning after an 
overnight fast at t= -2, 0, 4 weeks. Insulin and glucose levels were measured by a quality 
assured pathology laboratory (Southern IML Pathology), whilst plasma fatty acids were 
analysed by the Functional Food Group, School of Agriculture, Food and Wine, University of 
Adelaide using the methods described by Tu et al. [32]. Plasma total and high molecular 
weight (HMW) adiponectin concentrations were measured using a multimeric enzyme-linked 
immunosorbent assay (Alpco Diagnostics Inc, Salem, NH) run at the University of 
Wollongong. All adiponectin concentrations were measured in duplicate and any 
questionable results were re-tested. Care was taken to ensure all samples from the same 
participant were measured in the same assay run.   
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For the SNP analysis in ADIPOQ and FTO genes, saliva samples were collected for 
DNA extraction (Oragene, DNA Genotek, USA) at t=4 weeks. Due to the known ethnic 
variations in the prevalence of the tested SNPs and their functional polymorphisms [33, 34], 
saliva samples were collected only from participants of Caucasian ethnicity (n=25). Analysis 
of SNPs in ADIPOQ (rs266729) and FTO (rs9939609, rs8050136) was performed in 
duplicate using MALDI-TOF mass spectrometry (Sequenom MassARRAY iPLEX Platform).  
Statistical analysis: Data was analysed using SPSS (version 17.0, SPSS Chicago, IL, 2008). 
Normality of the data was determined using the Shapiro-Wilks test. Mean and standard 
deviation (SD) of all parametric variables were calculated, whilst median and inter-quartile 
range (IQR) were calculated for non-parametric variables.  
As the run-in period (t= -2–0 weeks) was designed to stabilise measures, reduce the 
within-participant variation and minimise the possibility of regression to the mean, the 
anthropometric and biochemical data from this period was not included in the analysis. As 
the literature suggests that research should focus on the change in adiponectin levels over 
time rather than single measures at an individual time point [35], changes in total and HMW 
adiponectin from t=0 to t=4 weeks were calculated and compared between groups via an 
independent samples t-test and Mann-Whitney test for parametric and non-parametric data 
respectively. This approach has been previously used in the adiponectin literature [15, 36]. 
Changes in total and HMW adiponectin from t=0 to t= 4 weeks within groups were calculated 
and compared via a paired samples t-test and a Wilcoxan signed ranks test for parametric and 
non-parametric data respectively 
Differences in other biochemical and anthropometric variables over time and between 
groups were measured via mixed between-within subjects ANOVA for parametric variables. 
For non-parametric dietary data, differences between groups were measured via a Mann-
Whitney test, whilst differences in biochemical and anthropometric variables within groups 
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over the duration of the intervention period (t=0–4 weeks) were measured via Wilcoxon 
signed ranks test. Differences in dietary variable and the Baecke questionnaire over the 
duration of the pilot study and between groups were also measured in this way. Due to a 
violation of the minimum cell frequency assumption of the Pearson’s chi-square analysis, 
Fisher’s exact test was used to determine if there was a significant difference between the 
allelic frequencies of SNPs in ADIPOQ and FTO in the ‘fish’ and ‘supplement’ groups. 
Compliance to recommended fish and supplement intake was measured as the number 
of fish or supplements consumed (calculated from returned products) as a percentage of the 
number of fish or supplements recommended provided. Mean and SD compliance of the 
study sample was then determined. 
 
Ethical approval was granted by the University of Wollongong Human Research 
Ethics Committee and informed consent was obtained for all participants. 
 
Results 
 
Of the n=93 individuals who expressed an interest in the study, n=30 met the 
inclusion criteria and were able to meet study requirements, and n=28 were present at t=0 and 
4 weeks (Figure 1). Total and HMW adiponectin results were excluded for one participant at 
all time points as a result of implausible findings.  
There were no significant differences in total and HMW adiponectin levels between 
study groups at t = 0 (Table 1). Change in HMW adiponectin over the intervention period 
was significantly different (p=0.009) between the ‘fish’ and ‘supplement’ groups. Significant 
decreases in HMW adiponectin levels over the duration of the study occurred in the 
‘supplement’ group (p=0.026), whilst non-significant increases were seen in the ‘fish’ group 
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(p=0.321). There were no significant changes in total adiponectin between groups or within 
groups. 
The percentage of EPA + DHA in plasma phospholipids increased significantly over 
the intervention period in both the ‘fish’ (p=0.001) and ‘supplement’ groups (p=0.001), but 
there was no significant difference between the groups at t=4 weeks (p=0.114) (Table 2). 
There were no significant differences within or between groups in any other anthropometric 
or biochemical variable. There was also no significant difference between groups in the 
allelic frequencies of SNPs in ADIPOQ and FTO genes (Table 3). 
The ‘fish’ group reported significantly increasing fish intake (p=0.001), and were 
consuming significantly higher amounts of fish than the ‘supplement’ group at the end of the 
intervention (p=0.000). Similarly, significantly higher intakes of LC n-3 PUFA from the diet 
were reported by the ‘fish’ group (p=0.000), however there was no significant difference 
between all LC n-3 PUFA consumed from dietary and supplement sources (p=0.285). During 
the intervention both the ‘fish’ and ‘supplement’ groups reported a reduced percentage 
energy intake from total and saturated fat (time effect: p=0.005, p=0.001 respectively) (table 
4). A significant interaction effect was also seen for percent energy from polyunsaturated fat 
(p=0.001).  
Mean and SD compliance for the ‘fish’ and ‘supplement’ groups was 87.51+16.54% 
and 90.23+11.20%, respectively.  
 
Discussion 
 
 The results of this study suggest that short-term consumption of fish and fish oil 
supplements do not have the same effect on HMW adiponectin levels. Over the course of a 
dietary intervention which incorporated the same amount of LC n-3 PUFA provided by either 
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fish or fish oil, a significantly different change in HMW adiponectin was found between 
groups. This was due to a small increase in HMW adiponectin in the ‘fish’ group, whilst the 
‘supplement’ group experienced a significant decrease. A similar pattern was seen for total 
adiponectin; however this did not reach statistical significance.  These changes occurred 
whilst factors known to be associated with adiponectin levels, such as weight and insulin 
levels [37], remained relatively constant.   
 This data suggests that the health benefits of fish may not be limited to the LC n-3 
PUFA content alone. It is currently not known why differential effects on HMW adiponectin 
were seen for fish and LC n-3 PUFA supplement consumption, and whilst this study was not 
designed to test mechanisms for change, some possibilities can be proposed. As a whole 
food, fish consists of a variety of additional nutrients and bioactive ingredients which could 
impact upon health. Consumption of fish protein has been linked to improvements in insulin 
sensitivity [38] and insulin response [39]. Furthermore, other components present in fish such 
as selenium and vitamin D have also been associated with a range of health benefits in 
humans [40, 41]. Whilst there has been no research conducted specifically investigating the 
influence of consumption of these nutrients on adiponectin levels, due to their known health 
benefits and as the intervention diets in the present study were matched for total LC n-3 
PUFA content, it is reasonable to suggest that compounds such as these, in addition to the LC 
n-3 PUFA, may have played a role in the changes in HMW adiponectin levels. The 
differential effects of fish and fish oil found in the present study are supported by research by 
Cobiac et al. [21], who found improvements in haemostatic factors in hyperlipidemic men 
following fish, but not fish oil, consumption. 
No previous research has compared the effects of fish and fish oil supplements on 
HMW adiponectin and only one study has done so using total adiponectin as an outcome. 
Ramel et al. [42] provided participants with salmon, cod, fish oil supplements or a control 
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diet of chicken over 12 weeks and found a reduction in total adiponectin in all groups, with 
no significant difference between groups. However, this study did not investigate changes in 
HMW adiponectin levels, which have been found to increase in concentration post-weight 
loss even when no changes in total adiponectin were seen [43]. Furthermore, unlike the 
present study, Ramel et al. [42] did not match the LC n-3 PUFA provided by the salmon and 
fish oil diets, making comparisons between the whole food and supplement problematic.  
Whilst there is a paucity of literature comparing the effects of fish and fish oil on 
HMW adiponectin, several studies have examined the impact of either fish or fish oil 
consumption on total adiponectin with varying results. Guebre-Egziabher et al. [12]; Kondo 
et al. [16]; and Lara et al. [14] found increases in total adiponectin levels following fish 
consumption, whilst Krebs et al. [13]; Sneddon et al. [15]; and Gammelmark et al. [17] found 
similar results after supplementation with fish oil. A limitation of these studies however, is 
that none examined the effect of fish consumption on HMW adiponectin. Only one previous 
study has examined the influence of either fish or fish oil supplements on HMW adiponectin, 
and did not see a significant effect of fish oil [44]. Given the known biological importance of 
HMW adiponectin, it is important to investigate this component in addition to total 
adiponectin, as non-significant changes in total adiponectin could mask a significant change 
in the HMW multimer, as was found in the present study. 
In the present study, a significant decrease in total and HMW adiponectin 
concentrations was found in the ‘supplement’ group. This contrasts with the results of 
previous studies which have found  increases in total adiponectin levels following 
supplementation with fish oil [13, 15, 17]; however this may be the result of methodological 
issues in previous research, such as the use of an ad libitum study diet [15], and failing to 
measure dietary LC n-3 PUFA intake [13, 15, 17]. A strength of the current study was that 
dietary variables were controlled for through a prescribed study diet, which were confirmed 
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through dietary assessment. The DH data indicated the ‘fish’ group consumed significantly 
higher amounts of LC n-3 PUFA from the diet than the ‘supplement’ group at 6 weeks (Table 
2). The inclusion of total LC n-3 PUFA consumed (calculated from returned supplements) 
suggested that both groups consumed similar amounts of LC n-3 PUFA from dietary and 
supplement sources as planned. This was supported by the plasma fatty acid analysis, which 
found no difference in levels of omega-3 or EPA + DHA between groups at the end of the 
intervention.    
Genetic analysis performed in the present study confirmed that there was no 
difference between the allelic frequency of SNPs in an adiponectin encoding gene and a gene 
associated with risk of obesity in the ‘fish’ and ‘supplement’ groups. These SNPs, which 
have been associated with alterations in circulating levels of adiponectin and risk factors for 
the metabolic syndrome and its associated diseases [23, 24, 34] could potentially confound 
the results of this study if variations existed between tested groups. However, similar 
genotypic and allelic frequencies of the tested SNPs found in both study groups suggests the 
findings of the present study were due to dietary changes rather than genetic variation 
between groups. This is a strength of the current study, as no previous studies have 
investigated genetic variation between groups. 
This study was limited by its small sample size and the short time period of the 
dietary intervention. However, as no previous research has compared the effects of fish and 
fish oil on HMW adiponectin, or indeed, many other health outcomes, this study has helped 
to establish proof of concept in this area. The lack of a separate control group is also a 
limitation of this study; however the run-in period addressed some of this problem by 
eliminating the effect of weight loss following commencement of dietary advice. Several 
other studies seeking to explore the effect of dietary components on adiponectin have also 
had no control group [12, 45].  
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 This study, which was the first to compare the effects of fish and fish oil supplements 
on total and HMW adiponectin, has shown that short-term consumption of fish and 
supplements do not have the same effect on this hormone. This finding was made in the 
absence of confounding factors such as dietary and genetic variations between groups.   
Whilst the changes in HMW adiponectin found in this study were relatively small, the 
differing patterns seen with fish and fish oil consumption imply dissimilar biological effects 
which necessitate further investigation. 
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Table 1: Mean + SD [median (IQR)] change in total and HMW adiponectin levels from t=0 to t=4 weeks 
1Paired samples t-test                                  2Wilcoxon signed ranks test                       
3Independent samples t-test                        4Mann-Whitney test 
 ‘Fish’ (n=12)  ‘Supplement’ (n=14)  p-value (between 
groups) 
 
 
t=0 t=4 Change (t=0 
to t=4 weeks) 
p-value 
(within group 
change) 
t=0 t=4 Change (t=0 to 
t=4 weeks) 
p-value 
(within group 
change) 
t=0 Change
Total 
adiponectin 
(ug/mL) 
6.93 + 2.82 
[6.69 (4.43 
– 8.38)] 
7.74 + 3.36 
[7.57 (4.97 – 
10.10)] 
0.81 + 1.95 
[0.34 (-0.37 – 
1.01)] 
0.1801 6.60 + 2.34 
[6.25 (4.31 
– 8.47)] 
6.46 + 2.51 
[5.96 (4.34 
– 8.91)] 
-0.14 + 2.05 
[0.51 (-1.19 – 
1.44)] 
0.7782 0.7463 0.8604 
 
HMW 
adiponectin 
(ug/mL) 
3.63 + 2.45 
[3.62 (1.25 
– 5.00)] 
3.92 + 2.96 
[3.62 (1.07 – 
5.32)] 
0.29 + 0.97 
[0.01 (-0.25 – 
0.40)] 
0.3211 3.39 + 2.07 
[2.63 (1.61 
–  4.96)] 
2.81 + 1.80 
[2.12 (1.30 
– 4.25)] 
-0.58 + 1.18    
[- 0.63 (-0.99 –  
-0.22)] 
0.0262 0.7893 0.0094 
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Table 2: Anthropometric and biochemical variables at t= -2, 0 and 4 weeks 
  ‘Fish’                            ‘Supplement’  p-value fish 
vs supps 
(between 
groups) 
Variable Mean (med.) SD 
(IQR) 
p-value 
fish 
(within 
group) 
Mean (med.) SD 
(IQR) 
p-value 
supps 
(within 
group) 
 
Males|Females 
(n) 
t= -2 wks  
t=0 wks 
t=4 wks 
 
5|10 
4|10 
4|10 
   
5|9 
5|9 
5|9 
   
Weight (kg) 
t=-2 wks 
 
t=0 wks 
        
t=4 wks 
 
83.11 (80.25) 
 
82.82 (79.60) 
 
82.78 (78.45) 
 
13.74 (71.15-
89.88) 
13.72 (70.90-
90.35) 
13.91 (71.95-
90.85) 
 
 
 
 
 
0.8615 
 
83.72 (80.50) 
 
82.80 (79.05) 
 
82.55 (78.45) 
 
13.96 (71.60–
100.55) 
13.55 (70.78–
98.68) 
13.86 (70.43-
98.33) 
 
 
 
 
 
0.5095 
 
 
 
1.0003 
 
0.9664 
BMI (kg/m2) 
t=-2 wks 
t=0 wks 
t=4 wks 
 
28.93 
28.83 
28.81 
 
2.98 
2.98 
3.01 
  
29.26 
28.95 
28.84 
 
3.00 
2.93 
2.93 
 Time:0.480 
Group:0.947 
Interaction: 
0.6476
Waist (cm) 
      t=-2 wks 
      t=0 wks 
      t=4 wks 
 
95.76 
94.96 
94.86 
 
9.57 
10.00 
9.90
  
98.57 
97.61 
97.11
 
10.70 
10.80 
10.84 
 Time:0.083 
Group:0.538 
Interaction: 
0.2536
Body fat (%) 
t=-2 wks 
t=0 wks2 
t=4 wks 
 
37.28 
36.89 
36.57 
 
7.16 
7.13 
6.5 
  
35.97 
35.09 
34.74 
 
7.27 
7.86 
8.10 
 Time:0.265 
Group:0.536 
Interaction: 
0.9556 
Glucose 
(mmol/L) 
       t=-2 wks 
       t=0 wks1 
       t=4 wks 
 
 
5.34 (5.30) 
5.32 (5.30) 
5.26 (5.10) 
 
 
0.38 (5.10-5.60) 
0.52 (5.05-5.65) 
0.38 (4.95–5.70) 
 
 
 
 
0.4085
 
 
5.21 (5.25) 
5.28 (5.25) 
5.14 (5.20) 
 
 
0.38(4.95-5.23) 
0.48(4.88-5.80) 
0.43(4.78-5.55) 
 
 
 
 
0.1785 
 
 
 
0.8194 
0.4273
Insulin (mU/L) 
       t=-2 wks 
       
t=0 wks1 
       
t=4 wks 
 
9.28 (8.10) 
 
9.28 (7.10) 
 
9.20 (8.10) 
 
4.75 (6.05-13.05) 
 
5.12 (5.80-12.00) 
 
3.38 (6.85-11.45) 
 
 
 
 
 
0.9375 
 
11.86 (9.80) 
 
12.23 (10.65) 
 
10.63 (9.15) 
 
7.24(6.90-
15.98) 
9.00(7.18-
12.70) 
9.15(5.68–
14.03) 
 
 
 
 
 
0.1985 
 
 
 
0.3023 
 
1.0003 
EPA + 
DHA(%) 
t=-2 wks 
t=0 wks1 
t=4 wks 
 
 
4.14 (4.03) 
4.94 (4.81) 
8.12 (8.90) 
 
 
0.64 (3.71-4.59) 
1.37 (4.04–5.41) 
2.08 (5.90–9.74) 
 
 
 
 
0.0015 
 
 
4.97 (4.75) 
5.33 (5.07) 
9.30 (9.54) 
 
 
 
0.88 (4.39-5.76) 
1.54 (4.27-5.89) 
1.53(8.37-
10.31) 
 
 
 
 
0.0015 
 
 
 
0.5503 
0.1143 
 
1Data available for n = 27 participants (n=13 fish, n=14 supplements) 
2Data excluded for n = 1 participant due to machinery malfunction (data available for: n=13 ‘fish’, n=14 ‘supplements’) 
3Mann-Whitney test                                4Independent t-test 
5Wilcoxon signed ranks test                                6Mixed between-within subjects ANOVA 
 
 
 
 
25 
 
Table 3: Allelic frequencies of SNPs in ADIPOQ (rs266729), and FTO (rs9939609, rs8050136) between ‘fish’ and ‘supplement’ groups 
 
 
 
 
 
 
 
 
 
1Fisher’s Exact Test 
2G allele associated with decreased levels of adiponectin 
43 
3A allele associated with increased risk of obesity 
27 
 ‘Fish’ ‘Supplement’ P-value1 
SNPs Genotypes Genotypes  
rs266729 
(ADIPOQ) 
CC GC/GG2 CC GC/GG2  
0.695 7 6 5 7 
rs9939609 
(FTO) 
TT AT/AA3 TT AT/AA3  
 
0.673 
3 10 4 8 
rs8050136 
(FTO) 
CC CA/AA3 CC CA/AA3  
 
0.673 
3 10 4 8 
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Table 4: Reported daily dietary intake and physical activity levels at t= -2 and 4 weeks 
 ‘Fish’ ‘Supplement’ 
 
p value fish vs 
supps (between 
groups)
Variables 
 
Mean 
(med.) 
SD 
(IQR) 
 
p-value fish 
(within 
group) 
Mean 
(med.) 
SD 
(IQR) 
p-value 
supps 
(within 
group) 
 
Fish (g) 
   t=-2 wks 
   
   t= 4 wks 
 
 
24.75 
(20.41) 
90.98 
(87.24) 
 
18.80 (10.15-
38.42) 
21.90 (84.58 – 
99.18) 
 
 
 
0.0013 
 
38.53 
(36.09) 
30.31 
(20.84) 
 
22.39 13.99-
31.01) 
29.54 (13.99 – 
31.01) 
 
 
 
0.1403 
 
0.064§ 
 
0.0001 
LC n-3 
PUFA (mg) 
   t=-2 wks 
  
   t=4 wks 
(diet only) 
   t=4 wks 
(diet + supp)     
 
 
359.06 
(211.78) 
 1901.16 
(1925.14) 
1901.16 
(1925.14) 
 
 
341.07 (150.20 – 
499.26) 
328.11 (1898.20 – 
1957.03) 
328.11 (1898.20 – 
1957.03)
 
 
 
 
 
 
0.0013 
 
 
502.81 
(493.44) 
339.65 
(264.83) 
1990.73 
(1982.53)
 
 
295.04 (230.02 – 
662.50) 
213.67 (203.78-
450.61) 
206.32 (1800.63–
2194.98)
 
 
 
 
 
 
0.0303 
 
 
 
 
0.0511 
0.0001 
 
0.2852 
Energy (kJ) 
   t=-2 wks 
    
   t=4 wks 
 
8173.06 
(8029.36) 
7536.06 
(7017.61) 
 
1740.14 (6581.85-
9435.74) 
 2287.46 (6414.04 
– 7888.74)
 
 
 
0.0743 
 
8584.13 
(9148.50) 
7680.67 
(6960.58)
 
2190.11 (6905.50-
10136.46)  
2514.00 (5840.40 
– 8892.84)
 
 
 
0.0563 
 
0.9625 
 
0.7691 
Protein (%E) 
   t=-2 wks 
   t=4 wks 
 
19.58 
20.20 
 
4.10 
2.53 
  
21.03 
21.33 
 
3.53 
5.06 
 Time: 0.553 
Group: 0.321 
Interaction: 0.8384
Total fat 
(%E) 
    t=-2 wks 
    t=4 wks 
 
 
31.50 
29.35 
 
 
4.18 
5.35 
  
 
30.61 
25.14 
 
 
6.75 
7.14 
 T 
Time: 0.005 
Group: 0.186 
Interaction: 0.1974
SFA (%E) 
   t=-2 wks 
   t=4 wks 
 
12.02 
8.99 
 
3.17 
2.09 
  
10.57 
9.20 
 
3.62 
2.90 
 Time: 0.001 
Group: 0.526 
Interaction: 0.1774
PUFA (%E) 
   t=-2 wks 
   t= 4 wks 
 
5.29 
6.84 
 
1.48 
1.27 
  
5.42 
4.37 
 
1.94 
1.56 
 Time: 0.505 
Group: 0.021 
Interaction: 0.0014
MUFA (%E) 
   t=-2 wks 
   t= 4 wks 
 
11.88 
11.73 
 
2.56 
3.17 
 
 
 
12.26 
9.39 
 
4.08 
3.30 
 Time: 0.060 
Group: 0.331 
Interaction: 0.0884
CHO (%E) 
   t=-2 wks 
   t= 4 wks 
 
43.63 
44.81 
 
7.15 
5.18 
  
44.04 
47.96 
 
5.62 
6.53 
 Time: 0.036 
Group: 0.389 
Interaction: 0.2444
EtOH (%E) 
   t=-2 wks 
    
   t= 4 wks 
 
3.40 (2.53) 
 
3.20 (2.48) 
 
2.64 (1.73 – 5.33) 
 
 2.79 (1.70 – 3.65) 
 
 
 
0.8753 
 
 2.11 (1.36) 
 
2.87 (2.26) 
 
2.24 (0.004 -
3.95) 
3.19 (0.19 – 
4.52) 
 
 
 
0.2793 
 
0.1861 
 
0.6031 
Baecke 
questionnaire 
    t=-2 wks 
    t= 4 wks6 
 
 
7.80 
7.65 
 
 
1.44 
1.33 
  
 
7.09 
7.37 
 
 
1.18 
1.11 
  
Time: 0.578 
Group: 0.302 
Interaction: 0.0724 
1Mann-Whitney test                            2Mann-Whitney test (compared to dietary LC n-3 PUFA at t= -2 weeks) 
3Wilcoxon signed ranks test                              4Mixed between-within subjects ANOVA 
5Independent t-test 
6Data available for n=27 participants (n=13 ‘fish’, n=14 ‘supplements’) 
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Figure 1: Enrolment, randomisation and available data for study participants over the 
duration of the study 
Expressed interest in study 
(n=93) 
Enrolled and randomised (n=30) 
Total (n=30)     ‘Fish’                 
(n=15)   
‘Supplement’        
(n=15)   
Withdrew prior 
to start (n=1)     
‘Fish’ 
(n=0) 
‘Supplement’ (n=1) 
-due to study time 
commitment 
t= -2 weeks 
(n=29)     
‘Fish’ 
(n=15) 
‘Supplement’        
(n=14)   
Withdrew (n=1)    ‘Fish’ 
(n=1) 
-due to a fear of needles 
  ‘Supplement’ 
(n=0) 
t=0 weeks 
(n=28)     
‘Fish’ (n=14) 
-percent body fat not 
available (n=1) 
-blood analyses not 
available (n=1) 
-excluded due to 
implausible adiponectin 
results (n=1) 
‘Supplement’         
(n=14)   
t=4 weeks 
(n=28)     
Genetic analysis 
(n=25) 
‘Fish’ (n=14) 
- physical activity not 
available (n=1) 
- excluded due to implausible 
adiponectin results (n=1) 
 
Genetic analysis (n=13) 
‘Supplement’         
(n=14)   
Genetic analysis 
(n=12) 
